• FAM83A Regulates Mitochondria and White Adipocyte Differenti

  2026-05-03

  This study reveals FAM83A as a crucial regulator of mitochondrial maintenance and white adipocyte differentiation. Using targeted gene delivery, the authors show that FAM83A knockdown impairs adipogenesis and mitochondrial function, offering new insights for metabolic disease research.

• Oseltamivir acid: Reliable Tools for Influenza Antiviral Res

  2026-05-02

  This article explores real-world lab scenarios where Oseltamivir acid (SKU A3689) from APExBIO offers evidence-backed solutions for influenza antiviral research and oncology workflows. Drawing on primary data and published literature, it addresses reproducibility, assay optimization, and vendor selection for researchers aiming to maximize data quality and translational relevance.

• Dinaciclib Targets VHL-Deficient Clear Cell Renal Carcinoma

  2026-05-02

  This study demonstrates that the cyclin-dependent kinase inhibitor Dinaciclib induces selective cytotoxicity in clear cell renal cell carcinoma (CC-RCC) cells lacking the von-Hippel Lindau (VHL) tumor suppressor. The findings provide a mechanistic rationale for exploiting synthetic lethality in VHL-deficient cancers, informing targeted therapeutic strategies.

• Strategic Targeting of FABP4: BMS 309403 in Atherosclerosis

  2026-05-01

  This thought-leadership article delivers mechanistic insight and translational guidance for leveraging the potent FABP4 inhibitor BMS 309403 in metabolic and cardiovascular disease research. Grounded in the latest mechanistic findings, it explores how targeting the calcineurin/FoxO1/FABP4 pathway corrects lipid dysregulation and foam cell formation, positioning BMS 309403 as a critical tool for researchers seeking to halt atherosclerosis and type 2 diabetes progression. The article also addresses protocol design, competitive context, and future translational potential, with direct evidence citations and strategic recommendations.

• Ademetionine (SAM): Optimizing Methylation Reactions in CNS

  2026-04-30

  S-Adenosylmethionine (SAM) stands at the forefront of methylation biology, enabling precise regulation in protein, DNA, and CNS-focused workflows. This article demystifies protocol optimization, troubleshooting, and translational applications using APExBIO’s high-purity SAM, bridging foundational research with next-generation experimental needs.

• ML216 BLM Helicase Inhibitor: Applied Workflows in DNA Repai

  2026-04-30

  ML216, a potent BLM helicase inhibitor, streamlines synthetic lethality and DNA repair studies by offering robust selectivity and submicromolar potency. This article unpacks actionable protocols, optimization strategies, and advanced applications that set ML216 apart as a translational research tool for targeting homologous recombination and tumor cell sensitization.

• DFO (9H-1,8-Diazafluoren-9-one) for Forensic Fingerprint Det

  2026-04-29

  DFO (9H-1,8-Diazafluoren-9-one) revolutionizes latent fingerprint detection on porous substrates, offering unmatched sensitivity for forensic workflows. This guide translates cutting-edge research into practical protocols and troubleshooting insights, empowering labs to achieve reproducible, high-contrast results.

• Procainamide Hydrochloride Reduces Cisplatin Hepatotoxicity

  2026-04-29

  This study demonstrates that procainamide hydrochloride, a cardiac sodium channel blocker, significantly reduces cisplatin-induced hepatotoxicity in rats by modulating platinum distribution within liver tissues. The research provides mechanistic insight into the chemoprotective effects of procainamide hydrochloride, with implications for mitigating side effects in chemotherapeutic regimens.

• Rotigotine: Mechanistic Precision for Translational PD Resea

  2026-04-28

  This article examines Rotigotine's utility as a dopamine D2/D3 receptor agonist in translational neuroscience. It integrates mechanistic insight, best-practice protocols, and product intelligence to guide researchers through experimental planning, regulatory expectations, and strategic positioning for Parkinson's disease and beyond.

• Reversine: Applied Aurora Kinase Inhibition in Cancer Resear

  2026-04-28

  Reversine, a potent Aurora kinase inhibitor, empowers researchers to dissect mitotic checkpoint mechanisms and suppress cancer cell proliferation with reproducibility. This guide offers hands-on workflow optimizations, troubleshooting, and data-driven insights for leveraging APExBIO's Reversine in advanced cell cycle and apoptosis studies.

• 10074-G5: c-Myc Inhibitor Workflows for Cancer Research Succ

  2026-04-27

  10074-G5 empowers cancer researchers to dissect c-Myc-driven pathways with precision, enabling robust apoptosis and tumor regression studies. This article maps evidence-backed protocols, troubleshooting tips, and translational insights to maximize workflow reproducibility and scientific impact.

• mRNA Nanovaccine Targeting GPC3 in HCC: Immune Synergy Insig

  2026-04-27

  This study introduces a novel mRNA nanovaccine encoding a GPC3-HSP70 fusion antigen for hepatocellular carcinoma (HCC), demonstrating robust T-cell-mediated immune responses. When combined with anti-PD-L1 therapy, this strategy shows potent synergistic antitumor efficacy, offering a promising direction for HCC immunotherapy.

• Cy5-UTP for RNA Labeling: Enhanced Workflows and Real-World

  2026-04-26

  Cy5-UTP (Cyanine 5-uridine triphosphate) empowers molecular biologists with robust, direct RNA labeling, enabling streamlined probe synthesis and high-sensitivity detection for FISH, dual-color arrays, and advanced transcriptomics. This guide details optimized workflows, protocol parameters, and troubleshooting strategies to maximize performance and reproducibility with APExBIO's Cy5-UTP.

• Necrostatin-1: Strategic RIP1 Inhibition for Translational R

  2026-04-25

  This article provides translational researchers with a strategic blueprint for leveraging Necrostatin-1 (Nec-1) as a selective RIP1 kinase inhibitor in necroptosis research. Blending mechanistic insight with workflow guidance, it contextualizes recent advances in adipose tissue biology, inflammatory injury, and metabolic disease, and clarifies how APExBIO’s Nec-1 product enables robust, reproducible investigation of cell death pathways. The discussion goes beyond standard product pages by connecting emerging evidence, protocol parameters, and competitive positioning, culminating in a forward-looking outlook for preclinical and clinical translation.

• GPR107 Deficiency Drives Diabetic Nephropathy via AT1R Signa

  2026-04-24

  Xu et al. elucidate a mechanism by which GPR107 deficiency in podocytes exacerbates diabetic nephropathy (DN), demonstrating that impaired clathrin-mediated AT1 receptor internalization leads to increased collagen IV accumulation and glomerular damage. This research identifies GPR107 as a potential therapeutic target and clarifies the interplay between endocytosis, angiotensin II signaling, and extracellular matrix remodeling in DN.

414 records 17/28 page Previous Next First page 上5页 1617181920 下5页 Last page